Brain Tumor Drug Receives Rare Disease Designations from the FDA (IMAGE)

Oklahoma Medical Research Foundation

Brain Tumor Drug Receives Rare Disease Designations from the FDA

Caption

The Food and Drug Administration has given Orphan Disease Designation and Rare Pediatric Disease Designation to OKN-007, an experimental brain cancer treatment currently in Phase 2 clinical trials at eight U.S. sites. The drug was discovered by Oklahoma Medical Research Foundation scientists Rheal Towner, Ph.D., (front) and Robert Floyd, Ph.D. (back).

Credit

Oklahoma Medical Research Foundation

Usage Restrictions

Photo may be used with credit.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.